Louisa Taylor
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
Taylor, Louisa; Wade, Philippa K.; Johnson, James E. C.; Aldighieri, Macha; Morlando, Sonia; Di Leva, Gianpiero; Kerr, Ian D.; Coyle, Beth
Authors
Philippa K. Wade
James E. C. Johnson
Macha Aldighieri
Sonia Morlando
Gianpiero Di Leva
Dr IAN KERR ian.kerr@nottingham.ac.uk
ASSOCIATE PROFESSOR
Professor BETH COYLE BETH.COYLE@NOTTINGHAM.AC.UK
PROFESSOR OF BRAIN TUMOUR MICROENVIRONMENT
Abstract
Therapy resistance represents an unmet challenge in the treatment of medulloblastoma. Accordingly, the identification of targets that mark drug-resistant cell populations, or drive the proliferation of resistant cells, may improve treatment strategies. To address this, we undertook a targeted approach focused on the multi-functional transcription factor YB-1. Genetic knockdown of YB-1 in Group 3 medulloblastoma cell lines diminished cell invasion in 3D in vitro assays and increased sensitivity to standard-of-care chemotherapeutic vincristine and anti-cancer agents panobinostat and JQ1. For vincristine, this occurred in part by YB-1-mediated transcriptional regulation of multi-drug resistance gene ABCB1, as determined by chromatin immunoprecipitation. Whole transcriptome sequencing of YB-1 knockdown cells identified a role for YB-1 in the regulation of tumourigenic processes, including lipid metabolism, cell death and survival and MYC and mTOR pathways. Stable cisplatin- and vincristine-tolerant Group 3 and SHH cell lines were generated to identify additional mechanisms driving resistance to standard-of-care medulloblastoma therapy. Next-generation sequencing revealed a vastly different transcriptomic landscape following chronic drug exposure, including a drug-tolerant seven-gene expression signature, common to all sequenced drug-tolerant cell lines, representing therapeutically targetable genes implicated in the acquisition of drug tolerance. Our findings provide significant insight into mechanisms and genes underlying therapy resistance in medulloblastoma.
Citation
Taylor, L., Wade, P. K., Johnson, J. E. C., Aldighieri, M., Morlando, S., Di Leva, G., Kerr, I. D., & Coyle, B. (2023). Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature. Cancers, 15(4), Article 1086. https://doi.org/10.3390/cancers15041086
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 4, 2023 |
Online Publication Date | Feb 8, 2023 |
Publication Date | 2023-02 |
Deposit Date | Feb 14, 2023 |
Publicly Available Date | Feb 15, 2023 |
Journal | Cancers |
Electronic ISSN | 2072-6694 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 15 |
Issue | 4 |
Article Number | 1086 |
DOI | https://doi.org/10.3390/cancers15041086 |
Keywords | medulloblastoma, drug resistance, cancer cell invasion, ABC transporter, YB-1, vincristine, metastasis |
Public URL | https://nottingham-repository.worktribe.com/output/17087514 |
Publisher URL | https://www.mdpi.com/2072-6694/15/4/1086 |
Files
cancers-15-01086
(3.1 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
A time-resolved Förster resonance energy transfer assay to investigate inhibitor binding to ABCG2
(2023)
Preprint / Working Paper
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search